Publications

Articles (peer-reviewed and indexed journals)


Del Rosso JQ, Kircik LH. Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol. 2014 Jul;13(7):s77-83.


Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the


Del Rosso JQ, Kircik LH. Not all topical corticosteroids are created equal! Optimizing therapeutic outcomes through better understanding of vehicle formulations, compound selection, and methods of application. J Drugs Dermatol. 2012 Dec;11(12):s5-8.


Kim GK. Del Rosso JQ. Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not? J Clin Aesthet Dermatol. 2011 Mar;4(3):17-26.


Del Rosso JQ, Pillai R, Moore R. Absence of degradation of tretinoin when benzoyl peroxide is combined with an optimized formulation of tretinoin gel (0.05%). J Clin Aesthet Dermatol. 2010 Oct;3(10):26-8.


Del Rosso Dermatology Research Center


Del Rosso JQ, Jitpraphai W, Bhambri S, Momin S. Clindamycin phosphate 1.2%-tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability. Cutis. 2008 May;81(5):405-8.


Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol. 2007 Jun;6(6):616-22.


